Resource data sheet
Prev.
Please review the QC test results indicated by check icon below as well as clone information before placing your order.

AxCA Luc+

Recombinant adenovirus expressing luciferase gene

Catalog number RDB02453
Resource name AxCA Luc+
Clone info. Recombinant adenovirus expressing luciferase gene under regulation with CAG promoter. DNA sequence is available.
Vector backbone pAxcw (Adenovirus)
Growth remarks 5 percent FCS is fine.
Gene/insert name firefly luc cDNA
Depositor|Developer Hamada, Hirofumi | Nakamura, Takafumi |
Other clones in our bank
External Database
firefly luc
            Reference sequence
              
             
            Sequence RDB02453z.seq
            Remarks, protocol and/or map (gif) RDB02453.gif

            Distribution information

            Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
            Terms and conditions for distribution The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit research. RECIPIENT must contact the DEPOSITOR in the case of application for any patents or commercial use based on the results from the use of the BIOLOGICAL RESOURCE. In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested.(Gene Ther., 10, 1152-1160 (2003).) In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested.
            Additional terms and conditions:
            Regarding resources containing CAG promoter: In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation for the CAG promoter (Niwa, H., Yamamura, K., Miyazaki, J., Gene 108 : 193-200, 1991) and an acknowledgment to Dr. Jun-ich Miyazaki of the Osaka University are requested.
            提供案内 (日本国内) [open/close]

            提供条件 非営利機関の非営利学術研究へ提供する。利用者が本件リソースを利用した研究成果に基づき特許申請、商業活動等を行う場合は、利用者は事前に寄託者に連絡する。利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する(Gene Ther., 10, 1152-1160 (2003).)。利用者は、研究成果の公表にあたって謝辞の表明を必要とする。
            付加的提供条件：
            CAGプロモータを含むリソースについて: 利用者は、研究成果の公表にあたってCAGプロモータの文献 (Niwa, H., Yamamura, K., Miyazaki, J., Gene 108 : 193-200, 1991)を引用し、大阪大学 宮崎純一博士への謝辞の表明を必要とする。
            備考 【追加提供依頼書】受入れ確認書(書式J)
            組換え体提供にかかる書式が必要です。

            Catalog # Resource name Availability Shipping form Fee (non-profit org.)
            RDB02453 AxCA Luc+ Under QC test. Please contact us. Virus, lysate of infected cell culture Please contact us.

            check Please wait for results of QC test to be uploaded. This clone will be sequenced a portion for examination.

            How to cite this biological resource

            Materials & Methods section:

            The AxCA Luc+ was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB02453).

            Reference section:

            Ninomiya, M., Koyama, H., Miyata, T., Hamada, H., Miyatake, S., Shigematsu, H., Takamoto, S., Ex vivo gene transfer of basic fibroblast growth factor improves cardiac function and blood flow in a swine chronic myocardial ischemia model. Gene Ther., 10, 1152-1160 (2003). PMID 12833124.

            Further references such as user reports and related articles (go to bottom)

            References and tips

            Featured content

            Featured content Arranged vector (English text)

            QC test results

            check Please wait for results of QC test to be uploaded. This clone will be sequenced a portion for examination.

            References

            Original, user report and related articles

            original Ninomiya, M., Ex vivo gene transfer of basic fibroblast growth factor improves cardiac function and blood flow in a swine chronic myocardial ischemia model. Gene Ther., 10, 1152-1160 (2003). PMID 12833124.
            user_report Masaike Y., Identification of dynamin-2-mediated endocytosis as a new target of osteoporosis drugs, bisphosphonates. Mol. Pharmacol., 77, 262-269 (2010). PMID 19903825.

            2023.05.02

            GNP_filter3_RDBDEP_html_230501.pl